Dream Incubator leads health-tech firm NIRAMAI’s Series A funding
Category: #health  By Ojaswita Kutepatil  Date: 2019-02-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Dream Incubator leads health-tech firm NIRAMAI’s Series A funding

NIRAMAI Health Analytix Pvt. Ltd., the Bengaluru-based breast cancer screening start-up, has reportedly raised around $6 million in Series A investment round that was led by Dream Incubator, a management consulting firm headquartered in Tokyo. Reportedly, Eto Munehiko, the Managing Director at Dream Incubator Advisory & Investment, India, will join NIRAMAI on board.

As per trusted sources, existing investors including Ankur Capital, Binny Bansal, pi Ventures and Axilor Ventures, along with Singapore-based venture fund Beenext, also participated in the funding round. Sources further cite that the start-up is anticipated to utilize the funds for scaling its Indian operations, hiring leading talent and seeking additional regulatory approvals for overseas expansion.

It has been reported that NIRAMAI has developed a non-contact, radiation-free device called Thermalytix, for early-stage breast cancer detection. A report by The Economic Times claims Dr. Geetha Manjunath, CEO, NIRAMAI, to have stated that if the NIRAMAI Thermalytix is institutionalised as a regular screening method, it endorses the potential to save numerous lives from breast cancer and other diseases as well.

Eto Munehiko was recently reported saying that the Tokyo-based company is excited to partner with NIRAMAI and believes firmly in the potential of its technology to deal better with global health issues at large. Eto further commented that Dream Incubator, having invested in over 160 companies, aims to support the international growth of NIRAMAI.

NIRAMAI, for those uninitiated, stands for non-invasive risk assessment with machine intelligence. The company uses artificial intelligence, together with big data analytics, to diagnose breast cancer at a prior stage. Its screening method, which is based on thermography principles, can detect tumours immensely earlier (about 5 years before) than a mammography or clinical examination usually takes. The start-up’s non-invasive, radiation-free device adds to its USP and further provides over 20 hospitals and diagnostic centres with training, installation and services, across Mysore, Bangalore, Dehradun, Pune, Mumbai and Hyderabad.



About Author

Ojaswita Kutepatil

Email: [email protected]   

Ojaswita Kutepatil

Ojaswita Kutepatil, a mechanical engineer by qualification, presently develops content for Market Size Forecasters, Algosonline, and other similar platforms. Having had a prior experience in Business Development and Technical Engineering, she now pens down articles pe...

Read More

More News By Ojaswita Kutepatil

Pepperfry to pump $12M in expansion & boost supply chain operations
Pepperfry to pump $12M in expansion & boost supply chain operations
By Ojaswita Kutepatil

The Mumbai-based online retailer also looks to step into areas like augmented/virtual reality to advance shopping experience.

Pepperfry, the online furniture & ...

Levi Strauss plans share market comeback after more than 3 decades
Levi Strauss plans share market comeback after more than 3 decades
By Ojaswita Kutepatil

In a recent turn of events, renowned Jeans manufacturer Levi Strauss & Co has reportedly filed documents for getting listed on the New York Stock Exchange, on the lookout for returning to public markets after over ...

NHS aims to roll out app therapy for children with mild depression
NHS aims to roll out app therapy for children with mild depression
By Ojaswita Kutepatil

The National Health Service reportedly aims to help children with mild depression through apps on their smartphones, post the recommendation of such devices by their treatment advisers. This service will be able to hel...